N

Nia Therapeutics

Precision neurostimulation therapy for memory loss

Overview

Nia Therapeutics is developing brain-computer interface technology and precision neurostimulation therapies to help people with memory loss, especially after traumatic brain injury. Its approach combines implantable neurotechnology that can read brain signals and deliver targeted electrical stimulation to restore memory function. Unlike general therapies, Nia aims to provide first-in-class devices that specifically treat memory loss caused by brain injury and related degenerative diseases. The company’s goal is to help the more than 27 million Americans living with memory impairment by offering a therapy that interprets brain activity and then stimulates the brain to improve memory performance.

Work here?Claim your company

About Nia Therapeutics

Simplify's Rating
Why Nia Therapeutics is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Robotics & AutomationHealthcare

Company Size

11-50

Company Stage

Early VC

Total Funding

$11.7M

Headquarters

Boston, MA

Founded

2018

Get referred to Nia Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • March 2026 FDA Breakthrough designation should speed IDE review and FDA interactions.
  • January 2026 sheep data showed stable 60-channel sensing and programmable stimulation across chronic implantation.
  • Nia raised $15.6 million on July 17, 2025, supporting its next regulatory milestones.

What critics are saying

  • Nia remains preclinical; its SNS has never been implanted in a patient.
  • The company still needs an IDE, first-in-human data, and pivotal evidence before commercialization.
  • If 2027 trials miss durable memory gains, the entire TBI-memory thesis collapses.

What makes Nia Therapeutics unique

  • Nia’s 60-channel closed-loop implant targets memory encoding, not generic brain stimulation.
  • March 13, 2026 FDA Breakthrough designation validates TBI-related memory loss as a first-in-class indication.
  • The platform’s personalized classifiers use each patient’s signals, unlike fixed-parameter neuromodulation devices.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$11.7M

Above

Industry Average

Funded Over

4 Rounds

Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Stock Options
  • Paid Vacation

Company News

Nia Therapeutics
Nov 10th, 2026
About Us | Nia TX – Innovating Memory Therapeutics

Meet the team behind Nia TX. Driven by neuroscience, engineering, and AI expertise, we're pioneering breakthrough therapies to enhance memory and cognitive performance for patients with TBI.

Business Wire
Mar 18th, 2026
FDA grants breakthrough designation to Nia's AI brain implant for TBI memory loss

Nia Therapeutics has received FDA Breakthrough Device Designation for its Smart Neurostimulation System, an AI-guided brain implant designed to treat episodic memory loss in adults with moderate-to-severe traumatic brain injury. The device is the first to receive breakthrough designation for TBI-related memory loss, addressing an unmet need affecting over 4.3 million Americans living with TBI-related disability. The fully implantable system records neural activity from 60 channels across four brain regions, using machine-learning to detect moments of impaired memory encoding and deliver targeted electrical stimulation. A randomised, sham-controlled study showed the closed-loop approach improved recall by 19% in neurosurgical patients. Founded in 2018, Nia Therapeutics plans to submit an Investigational Device Exemption application this year to support a first-in-human early feasibility study.

Silverwood Partners
Jul 23rd, 2025
Healthcare Private Placement and M&A Transactions Review Week Ending July 20, 2025

Nia Therapeutics: The company raised $15.6 million of venture funding from Ben Franklin Technology Partners, Paeonia Group and other undisclosed investors on July 17, 2025.

U.S. Securities and Exchange Commission
Dec 20th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
Dec 20th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Recently Posted Jobs

Sign up to get curated job recommendations

Nia Therapeutics is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs